UK Markets close in 58 mins

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
40.51+0.02 (+0.05%)
As of 10:32AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close40.49
Open40.43
Bid40.45 x 1400
Ask40.46 x 4000
Day's range40.38 - 40.55
52-week range33.26 - 42.40
Volume529,985
Avg. volume4,678,119
Market cap100.155B
Beta (5Y monthly)0.36
PE ratio (TTM)14.07
EPS (TTM)2.88
Earnings date01 Feb 2017 - 06 Feb 2017
Forward dividend & yield2.12 (5.62%)
Ex-dividend date18 Feb 2021
1y target est47.27
  • Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
    Zacks

    Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

    Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

  • AstraZeneca's 'Storm Chaser' COVID trial misses goal but offers some hope
    Yahoo Finance UK

    AstraZeneca's 'Storm Chaser' COVID trial misses goal but offers some hope

    AZD7442 failed to meet the main goal of stopping people developing symptomatic COVID-19 but did offer some hope that it could help people who had not yet come into contact with the virus.

  • Why iTeos Therapeutics Stock Soared Today
    Motley Fool

    Why iTeos Therapeutics Stock Soared Today

    Shares of iTeos Therapeutics (NASDAQ: ITOS) surged 37% on Monday after it reached an agreement with GlaxoSmithKline (NYSE: GSK) to co-develop an experimental cancer treatment known as EOS-448. EOS-448 is a monoclonal antibody treatment for patients with cancer. GlaxoSmithKline also intends to begin new combination studies of EOS-448 with some of its other immuno-oncology therapies next year.